Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 23,671 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten sold 23,671 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now owns 99,652 shares of the company’s stock, valued at $3,522,698.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Dirk Kersten also recently made the following trade(s):

• On Wednesday, September 25th, Dirk Kersten sold 2,357 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.06, for a total transaction of $82,636.42.
• On Monday, September 23rd, Dirk Kersten sold 40,831 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.32, for a total transaction of $1,442,150.92.
• On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock traded up $0.51 on Friday, hitting $35.24. The company had a trading volume of 1,596,541 shares, compared to its average volume of 1,540,210. The firm has a market capitalization of $3.08 billion, a P/E ratio of -8.88 and a beta of 1.05. Dyne Therapeutics, Inc. has a twelve month low of $6.40 and a twelve month high of $47.45. The stock has a 50-day moving average of $37.55 and a 200-day moving average of $34.49.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.02. Equities analysts predict that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its holdings in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the last quarter. Amalgamated Bank boosted its holdings in Dyne Therapeutics by 39.9% during the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after purchasing an additional 796 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Dyne Therapeutics during the second quarter worth $203,000. Ameritas Investment Partners Inc. raised its position in Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after acquiring an additional 1,291 shares in the last quarter. Finally, Farallon Capital Management LLC bought a new stake in Dyne Therapeutics during the second quarter worth $212,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Oppenheimer reissued an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. boosted their price target on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 9th. Stifel Nicolaus boosted their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Guggenheim boosted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Finally, StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.